A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Description
Phase
N/AInclusion and Exclusion Criteria
- Diagnosis of non-infectious intermediate, posterior, or pan
- uveitis in at least one eye
- Active uveitic disease in at least one eye
- Currently on one of the following stable treatment regimens for uveitis: oral corticosteroids; systemic immunosuppressive medication; a combination of oral corticosteroids with at least one systemic immunosuppressive medication
- Effective contraceptive measures
- Infectious uveitis and masquerade syndromes
- Isolated anterior uveitis
- Contraindication to mydriatics
- History of allergic or anaphylactic reactions to monoclonal antibodies
- Active tuberculosis disease
- History of recurrent infection or predisposition to infection; active ocular infection
- Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply
Sites
Please contact Yoon Hee Kim to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI